06:00 , Oct 23, 2018 |  BC Extra  |  Company News

Takeda licenses Enterome's Crohn's disease therapy

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered with Enterome Bioscience S.A. (Paris, France) to co-develop the biotech's EB8018 to treat Crohn's disease. The companies will share global development costs as well as U.S. commercialization costs and...
21:17 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Microbiome company Enterome raises €32M

Enterome Bioscience S.A. (Paris, France) raised €32 million ($38 million) on Jan. 4 in a series D round. New investors Principia SGR and Bristol-Myers Squibb Co. (NYSE:BMY) and all existing investors -- Seventure, which invested...
08:03 , Jan 4, 2018 |  BC Extra  |  Financial News

Microbiome company Enterome raises €32M

Enterome Bioscience S.A. (Paris, France) raised €32 million ($38 million) in a series D round. New investors Principia SGR and Bristol-Myers Squibb Co. (NYSE:BMY) and all existing investors -- Seventure, which invested via several funds...
23:46 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Enterome's CD candidate well tolerated in Phase I

Enterome Bioscience S.A. (Paris, France) reported data from a Phase I trial in about 60 healthy volunteers showing that single and multiple ascending oral doses of Crohn's disease candidate EB8018 (EP8018) were well tolerated. The...
00:41 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

EB8018: Ph I started

Enterome began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate single and multiple ascending doses of oral EB8018 in about 60 healthy volunteers. Enterome has exclusive, worldwide rights to EB8018 from Vertex (see BioCentury,...
21:06 , Nov 5, 2016 |  BioCentury  |  Finance

Vive la biotech

The French biotech sector has historically lagged other European countries such as the U.K. and Germany in both financings and deals. But a fledgling group of public bellwethers and a crop of innovative private companies...
07:00 , May 9, 2016 |  BioCentury  |  Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...
07:00 , May 2, 2016 |  BC Week In Review  |  Company News

Vertex, Enterome Bioscience deal

Vertex granted Enterome exclusive, worldwide rights to small molecule antagonists of bacterial fimbrial adhesin (fimH) , including lead compound EB 8018 , to treat inflammatory bowel disease (IBD). Enterome said it plans to start clinical...
01:17 , Apr 21, 2016 |  BC Extra  |  Financial News

Microbiome plays Second Genome, Enterome raise funds

Second Genome Inc. (South San Francisco, Calif.) and Enterome Bioscience S.A. (Paris, France) each raised venture rounds on Wednesday. Second Genome raised $42.6 million in a series B round co-led by new investors Pfizer Venture...
08:00 , Dec 3, 2015 |  BC Innovations  |  Product R&D

Microbiome at the checkpoint

The growing belief that the microbiome can be harnessed to treat cancer has arguably received its biggest boost to date with the publication of two papers in...